



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : C07D 307/52</p>	<p>A1</p>	<p>(11) International Publication Number: WO 96/17839 (43) International Publication Date: 13 June 1996 (13.06.96)</p>
<p>(21) International Application Number: PCT/US95/15385 (22) International Filing Date: 20 November 1995 (20.11.95) (30) Priority Data: 351,985 8 December 1994 (08.12.94) US 542,408 16 November 1995 (16.11.95) US (71) Applicant: HOECHST MARION ROUSSEL, INC. [US/US]; 2110 East Galbraith Road, P.O. Box 156300, Cincinnati, OH 45215-6300 (US). (72) Inventor: STROM, Robert, M.; 789 W. Chippewa River Road, Midland, MI 48640 (US). (74) Agent: STEMERICK, David, M.; Hoechst Marion Roussel, Inc., 2110 East Galbraith Road, P.O. Box 156300, Cincinnati, OH 45215-6300 (US).</p>		<p>(81) Designated States: AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, LS, MW, SD, SZ, UG). Published <i>With international search report.</i></p>
<p>(54) Title: NOVEL PROCESSES FOR PREPARING RANITIDINE (57) Abstract The present invention relates to a novel method for preparing ranitidine and pharmaceutically acceptable salts thereof.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgystan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

5

10 NOVEL PROCESSES FOR PREPARING RANITIDINE

The present invention relates to a novel process for preparing ranitidine, N-[2-[[[5-(dimethylamino)methyl-2-
15 furanyl]methyl]thio]ethyl]-N'-methyl-2-nitro-1,1-ethenediamine, and pharmaceutically acceptable salts thereof, an antagonist of the H₂-histamine receptor which is useful in the treatment of gastric and peptic ulcers (U.S. Patent No. 4,128,658, December 5, 1978). The process of
20 the present invention provides a novel and efficient method for preparing ranitidine and pharmaceutically acceptable salts thereof.

SUMMARY OF THE INVENTION

25

The present invention provides a novel process for preparing ranitidine and pharmaceutically acceptable salts thereof, comprising:

30 reacting 2-nitromethylene-thiazolidine with methylamine to give a reaction mixture and then reacting the reaction mixture with an appropriate 5-
[(dimethylamino)methyl]-furan derivative.

35


DETAILED DESCRIPTION OF THE INVENTION

As used in this application:

5

a) the terms "ranitidine" or "N-[2-[[[5-(dimethylamino)methyl-2-furanyl]methyl]thio]ethyl]-N'-methyl-2-nitro-1,1-ethenediamine" refer to a compound of the formula

10




15

b) the term "pharmaceutically acceptable salts" refers to acid addition salts.

The expression "pharmaceutically acceptable acid addition salts" is intended to apply to any non-toxic organic or inorganic acid addition salt of ranitidine. Illustrative inorganic acids which form suitable salts include hydrochloric, hydrobromic, sulphuric, and phosphoric acid and acid metal salts such as sodium monohydrogen orthophosphate, and potassium hydrogen sulfate. Illustrative organic acids which form suitable salts include the mono-, di-, and tricarboxylic acids. Illustrative of such acids are for example, acetic, glycolic, lactic, pyruvic, malonic, succinic, glutaric, fumaric, malic, tartaric, citric, ascorbic, maleic, hydroxymaleic, benzoic, hydroxybenzoic, phenylacetic, cinnamic, salicylic, 2-phenoxybenzoic, and sulfonic acids such as p-toluenesulfonic acid, methanesulfonic acid and 2-hydroxyethanesulfonic acid. Such salts can exist in either a hydrated or substantially anhydrous form.

The preparation of ranitidine utilizing the economical starting material 2-nitromethylene-thiazolidine (1) is desirable. Such a process would probably proceed through N-(2-mercaptoethyl)-N'-methyl-2-nitro-1,1-ethenediamine (2). Contrary to reports in the art, N-(2-mercaptoethyl)-N'-methyl-2-nitro-1,1-ethenediamine (2) is not an isolatable solid characterized by a melting point of about 177-180°C (dec). In fact, compound 2 may not be isolatable. The difficulties in isolating compound 2 are explained by the equilibrium and reactions shown in Reaction Scheme A.

Reaction Scheme A



As disclosed in Reaction Scheme A, when 2-nitromethylene-thiazolidine (1) is contacted with methylamine an equilibrium is established between the addition product, N-(2-mercaptoethyl)-N'-methyl-2-nitro-1,1-ethenediamine (2) and 2-nitromethylene-thiazolidine (1). Also, as is appreciated in the art, N-(2-mercaptoethyl)-N'-methyl-2-nitro-1,1-ethenediamine (2), in the presence of a base, such as methylamine, is also in equilibrium with the mercaptide anion derived therefrom.

The equilibrium concentration of compound 2 depends on various factors, including the concentration of methylamine. The equilibrium constant for the above reaction of compound 1 with methylamine to give compound 2 is derived from the expression:

$$\frac{[\text{compound 2}]}{[\text{compound 1}] [\text{methylamine}]}$$

wherein the terms "[compound 2]" refers to the equilibrium concentration of compound 2 in mol/L, "[compound 1]" refers to the equilibrium concentration of compound 1 in mol/L, and "[methylamine]" refers to the equilibrium concentration of methylamine in mol/L. In acetonitrile and isopropanol that equilibrium constant has a value of about 2 L/mol.

In addition to reacting by loss of methylamine to give compound 1, compound 2 can, in the presence of air or other oxidizing conditions, form the disulfide (3), N-methyl-N'-[2-[2-(N"-methyl-2-nitro-1,1-ethenediamine)ethyl]disulfanyl]ethyl]-2-nitro-1,1-ethenediamine, an isolatable solid characterized by a melting point of about 177-180°C (dec), which was previously reported in the art to be compound 2. Even though disulfide 3 may be a useful intermediate for forming ranitidine utilizing other processes, it represents


a non-productive by-product in a process which directly uses compound 2 as an intermediate.

5 Also, compound 2 can cyclize to form 3-methylamino-5,6-dihydro-[1,4]thiazin-2-one oxime, compound 4. In the depiction of compound 4 it is understood that the compound 3-methylamino-5,6-dihydro-[1,4]thiazin-2-one oxime can exist in a number of isomeric and tautomeric states. The
10 formation of compound 4 is detrimental to any process which uses compound 2 because it is not in equilibrium with compound 2 and represents a non-productive by-product.

It has now been found that the direct use of N-(2-
15 mercaptoethyl)-N'-methyl-2-nitro-1,1-ethenediamine (2) can be accomplished by processes which utilize the equilibria disclosed in Reaction Scheme A. The instant process utilizes the equilibria disclosed in Reaction Scheme A to prepare ranitidine using N-(2-mercaptoethyl)-N'-methyl-2-
20 nitro-1,1-ethenediamine (2), without isolation, in a simple and economical one-pot process. The instant process uses N-(2-mercaptoethyl)-N'-methyl-2-nitro-1,1-ethenediamine (2) prepared from simple and readily available starting materials, 2-nitromethylene-thiazolidine (1) and
25 methylamine. Thus, the instant invention provides a simple and economical process for preparing ranitidine.

A general synthetic procedure is set forth in Reaction Scheme 1 for preparing ranitidine from 2-nitromethylene-
30 thiazolidine. In Reaction Scheme 1, reagents, techniques, and procedures used are well known and appreciated by one of ordinary skill in the art.

Reaction Scheme 1



In Reaction Scheme 1, 2-nitromethylene-thiazolidine (1) is contacted with methylamine to give a reaction mixture and then the reaction mixture is contacted with an appropriate 5-[(dimethylamino)methyl]-furan derivative (5) to give ranitidine.

An appropriate 5-[(dimethylamino)methyl]-furan derivative is one in which L is a suitable leaving group. A suitable leaving groups, L, is one which can be displaced to give ranitidine. Suitable leaving groups include but are not limited to chloro, bromo, mesylate, tosylate, benzenesulfonate, and the like, with chloro being preferred. The conversion of hydroxy groups to leaving groups such as chloro, bromo, mesylate, tosylate, and benzenesulfonate is well known and appreciated in the art.

For example, 2-nitromethylene-thiazolidine is contacted with from about 1 to 20 molar equivalents of methylamine to

give a reaction mixture. Initially contacting 2-nitromethylene-thiazolidine with 1 to 8 molar equivalents of methylamine being preferred and 2 to 4 molar equivalents of 5 methylamine being more preferred. Additional methylamine may be added during the course of the reaction up to about 20 molar equivalents.

The reaction mixture is formed at a temperature of from 10 about -20°C to about 80°C with temperatures of about -10°C to about 50°C being preferred. The reaction is carried out under an inert atmosphere, for example under nitrogen or argon.

15 The reaction mixture is formed in a substantially anhydrous solvent, such as acetonitrile, methanol, ethanol, propanol, butanol, isopropanol, and higher alcohols, such as pentanol, hexanol, heptanol, or octanol, with acetonitrile, methanol, ethanol, and isopropanol being preferred;
20 acetonitrile and isopropanol being more preferred; and acetonitrile being most preferred. Optionally, the solvent may be degassed to remove oxygen.

After a time, the reaction mixture is contacted with 25 from about 0.6 to 1.5 molar equivalents of an appropriate 5-[(dimethylamino)methyl]-furan derivative or a salt thereof. The use of from about 0.9 to 1.2 molar equivalents of an appropriate 5-[(dimethylamino)methyl]-furan derivative or a salt thereof is preferred with the use of from about 1.0 to 30 1.1 molar equivalents of an appropriate 5-[(dimethylamino)methyl]-furan derivative or a salt thereof being more preferred and the use of about 1.05 molar equivalents of an appropriate 5-[(dimethylamino)methyl]-furan derivative or a salt thereof being most preferred. The use of a salt of an 35 appropriate 5-[(dimethylamino)methyl]-furan derivative is preferred.

The reaction is carried out at temperatures of from about -20°C to about 80°C with temperatures of from about -10°C to about 50°C being preferred.

5

When the reaction mixture is contacted with an appropriate 5-[(dimethylamino)methyl]-furan derivative or a salt thereof, the addition of an appropriate 5-[(dimethylamino)methyl]-furan derivative or a salt thereof
10 to the reaction mixture is preferred. The reaction mixture and an appropriate 5-[(dimethylamino)methyl]-furan derivative or a salt thereof can be contacted portionwise, for example, as a single portion or a plurality of portions, or continuously.

15

When the addition is carried out using a plurality of portions, the amount of 5-[(dimethylamino)methyl]-furan derivative or a salt thereof added in each portion can be decreased throughout the reaction. When the addition is
20 carried out continuously, the rate of addition of 5-[(dimethylamino)methyl]-furan derivative or a salt thereof can be decreased throughout the reaction. The addition of decreasing amounts of 5-[(dimethylamino)methyl]-furan derivative or a salt throughout the reaction is preferred.

25

When the addition is carried out portionwise, the temperature of the reaction can be substantially the same throughout the addition at temperatures of from about -20°C to about 80°C with temperatures of from about -10°C to about
30 50°C being preferred.

Alternatively, when the addition is carried out portionwise, the temperature of the reaction can be cycled such that a reaction mixture is formed at a relatively
35 higher temperature, such as about 30°C to about 50°C and then the temperature of the reaction mixture is lowered to about -20°C to about 20°C before a portion of an appropriate 5-[(dimethylamino)methyl]-furan derivative or a salt thereof

is added. After a time, the temperature can be again raised to a relatively higher temperature, such as about 30°C to 50°C and then the temperature of the reaction mixture is lowered to about -20°C to about 20°C before another portion of an appropriate 5-[(dimethylamino)methyl]-furan derivative or a salt thereof is added. This temperature cycling can be continued until the addition of an appropriate 5-[(dimethylamino)methyl]-furan derivative or a salt thereof is complete.

When the addition is carried out continuously, the temperature of the reaction can be substantially the same throughout the addition at temperatures of from about -20°C to about 80°C with temperatures of from about -10°C to about 50°C being preferred and temperatures of from about 20°C to about 50°C being more preferred.

Alternatively, when the addition is carried out continuously, a reaction mixture can be formed at a relatively high temperature, such as about 30°C to about 50°C then lowered to a temperature of about -20°C to about 20°C before contacting in a reaction zone, such as a continuous reactor cell, with an appropriate 5-[(dimethylamino)methyl]-furan derivative or a salt thereof at a substantially similar lower temperature of about -20°C to about 20°C.

The addition can be accomplished by contacting the reaction mixture with an appropriate 5-[(dimethylamino)methyl]-furan derivative or a salt thereof, either neat or as a solution or slurry in a substantially anhydrous solvent.

When a solution or slurry of an appropriate 5-[(dimethylamino)methyl]-furan derivative or a salt thereof is used, the addition can be carried out using the a different substantially anhydrous solvent or, more

-10-

conveniently, the same substantially anhydrous solvent that is used to form the reaction mixture. When the addition is carried out using a solution or slurry, adjuncts may be used to increase the solubility of the appropriate 5-
5 [(dimethylamino) methyl]-furan derivative or a salt thereof. For example, when an appropriate 5-[(dimethylamino)methyl]-furan derivative or a salt thereof is added as a solution or slurry in acetonitrile, adjuncts, such as methanesulfonic
10 acid or hydrochloric acid, may be added.

The reaction is carried out in the presence of from about 1 to 20 molar equivalents of a suitable base. When a salt of an appropriate 5-[(dimethylamino)methyl]-furan
15 derivative is used the reaction is carried out using from about 2 to 20 molar equivalents of a suitable base. When a salt of an appropriate 5-[(dimethylamino)methyl]-furan derivative is added in a solution or slurry containing an adjunct the reaction is carried out using from about 3 to 20
20 molar equivalents of a suitable base. A suitable base may be added portionwise over the course of the reaction. The use of methylamine as the suitable base is preferred, however, other bases may be used, such as triethylamine and diisopropylethylamine.

25

The product can be isolation by methods well known and appreciated in the art, such as extraction and evaporation. The product can be purified by methods well known and appreciated in the art, such as chromatography and
30 recrystallization.

In an optional step, ranitidine can be contacted, as is well known in the art, with a pharmaceutically acceptable acid to form a pharmaceutically acceptable salt thereof
35 which can be further purified by methods well known and appreciated in the art, such as recrystallization.

-11-

The foregoing process is exemplified by the procedures given below. These procedures are understood to be illustrative only and are not intended to limit the scope of the invention in any way. As used in the procedures, the following terms have the meanings indicated: "mg" refers to milligrams; "g" refers to grams; "kg" refers to kilograms; "mmol" refers to millimoles; "mol" refers to moles; "mL" refers to milliliters; "L" refers to liters; "mp" refers to melting point; "°C" refers to degrees Celsius; "dec" refers to decomposition; "M" refers to molar.

EXAMPLE 1

15 1.1 Synthesis of 5-[(dimethylamino)methyl]-2-(chloromethyl)-furan hydrochloride

Combine 5-[(dimethylamino)methyl]-furfuryl alcohol (25 g) and dichloromethane (100 mL). Cool to 0°C. Add dropwise, thionyl chloride (20 mL) at such a rate that the reaction does not rise above 5°C. After 0.5 hours, evaporate *in vacuo* to give a residue, Recrystallize the residue from ethanol to give the title compound: mp; 164-165°C (dec).

25 1.2 Synthesis of N-[2-[[[5-(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-N'-methyl-2-nitro-1,1-ethenediamine

Combine 2-nitromethylene-thiazolidine (10.0 g) and isopropanol (40 mL). Add methylamine (14.7 g). Heat to 40°C. After 5 minutes, add 5-[(dimethylamino)methyl]-2-(chloromethyl)-furan hydrochloride (13.05 g) portionwise over 1.5 hours. After 3 hours, cool to ambient temperature. Add aqueous sodium hydroxide solution (11.6 g, 50% by weight) and water (20 g). Extract repeatedly with methyl isobutyl ketone. Combine the organic layers and evaporate *in vacuo* to give the title compound.

EXAMPLE 25 2.1 Synthesis of 5-[(dimethylamino)methyl]-2-(chloromethyl)-furan hydrochloride

Combine 5-[(dimethylamino)methyl]-furfuryl alcohol hydrochloride (201 g, 1.05 mol) and acetonitrile (500 mL). Add dropwise, thionyl chloride (119 g, 1.0 mol) at such a
10 rate that the temperature of the reaction is maintained at about 30°C to 35°C. After the addition of thionyl chloride is complete, add methanesulfonic acid (144 g, 1.5 mol) while removing sulfur dioxide and acetonitrile by
15 distillation. Stop the distillation when about 250 mL of distillate has been collected to give the title compound as a solution.

20 2.2 Synthesis of N-[2-[[[5-(dimethylamino)methyl-2-furanyl]methyl]thio]ethyl]-N'-methyl-2-nitro-1,1-ethenediamine

Combine 2-nitromethylene-thiazolidine (146 g, 1.0 mol) and acetonitrile (250 mL). Heat to 40°C. Add methylamine (93 g, 3 mol). Cool to about 25°C. Add a solution of 5-
25 [(dimethylamino)methyl]-2-(chloromethyl)-furan hydrochloride (1.05 mol) as obtained in Example 2.1, maintained at 50°C to 60°C to prevent crystallization, continuously over 5.5 hours and methylamine (5 mol) continuously over 2.5 hours. The addition trajectories of
30 5-[(dimethylamino)methyl]-2-(chloromethyl)-furan hydrochloride solution and methylamine are summarized in Table 1.

Table 1

	Time, (hr:min)	Temp. (°C)	Methylamine (total g)	Solution from Example 2.1 (total g)
5	0:00	24	93	0
	0:25	27	119	97
	0:55	27	149	203
10	1:27	26	181	303
	2:35	27	248	448
	2:52	25	248	467
	3:40	27	248	517
	5:30	26	248	579

15 When the reaction is complete, add a solution of sodium acetate (370 g) in water (780 mL). Separate the layers and extract the aqueous layer twice with acetonitrile. Combine the organic layers and evaporate *in vacuo* to give a residue.

20 Partition the residue between methyl isobutyl ketone (1680 mL) and aqueous 10% potassium carbonate solution. Separate the layers and extract the aqueous layer with methyl isobutyl ketone (1680 mL). Combine the organic layers extract with water. Evaporate the organic layer *in vacuo* to

25 give a residue. Recrystallize the residue from methyl isobutyl ketone to give the title compound.

EXAMPLE 3

30 3.1 Synthesis of 5-[(dimethylamino)methyl]-2-(chloromethyl)-furan hydrochloride

Combine 5-[(dimethylamino)methyl]-furfuryl alcohol hydrochloride (210 g, 1.1 mol) and acetonitrile (500 mL). Cool to about 0°C. Add dropwise, thionyl chloride (113 g, 0.95 mol) over 30 minutes maintaining the temperature of

35 the reaction below about 5°C. After the addition of thionyl chloride is complete, distill *in vacuo* to remove about 250 mL of distillate. Add methanesulfonic acid (144 g, 1.5 mol) to give the title compound as a solution.

3.2 Synthesis of N-[2-[[[5-(dimethylamino)methyl-2-furanyl]methyl]thio]ethyl]-N'-methyl-2-nitro-1,1-ethenediamine

5 Combine 2-nitromethylene-thiazolidine (146 g, 1.0 mol) and acetonitrile (250 mL). Heat to 40°C. Add methylamine (90 g). After 30 minutes, cool to about -10°C. Add a solution of 5-[(dimethylamino)methyl]-2-(chloromethyl)-
10 furan hydrochloride as obtained in Example 3.1, maintained at 50°C to 60°C to prevent crystallization (about 322 g of solution over 3 hours). Add methylamine (120 g). Warm to 40°C while adding methylamine (65 g). After 30 minutes, cool to 0°C. Add the remainder of the solution of 5-
15 [(dimethylamino)methyl]-2-(chloromethyl)-furan hydrochloride. After the addition is complete, evaporate *in vacuo* to give a residue. Partition the residue between methyl isobutyl ketone and aqueous 10% potassium carbonate solution. Separate the layers and extract the aqueous
20 layer with methyl isobutyl ketone. Combine the organic layers extract with water. Evaporate the organic layer *in vacuo* to give a residue. Recrystallize the residue from methyl isobutyl ketone to give the title compound.

25

EXAMPLE 4

4.1 Synthesis of 5-[(dimethylamino)methyl]-2-(chloromethyl)-furan hydrochloride

30 Combine 5-[(dimethylamino)methyl]-furfuryl alcohol hydrochloride (1.72 kg, 8.97 mol) and acetonitrile (4.3 L). Cool to about 10°C. Add thionyl chloride (1.02 kg, 8.54 mol) dropwise, while maintaining the temperature of the reaction at below about 40°C. After the addition of thionyl chloride is complete, add methanesulfonic acid (1.3
35 kg, 13.5 mol). Distill to remove about 1.8 L of distillate to give the title compound as a solution.

4.2 Synthesis of N-[2-[[[5-(dimethylamino)methyl-2-furanyl]methyl]thio]ethyl]-N'-methyl-2-nitro-1,1-ethenediamine

5 Combine 2-nitromethylene-thiazolidine (1.25 kg, 8.53 mol) and acetonitrile (2.15 L). Add methylamine (0.85 kg). While maintaining the temperature of the reaction at below 35°C, add a solution of 5-[(dimethylamino)methyl]-2-(chloromethyl)-furan hydrochloride as obtained in Example
10 4.1, maintained at 50°C to 60°C to prevent crystallization. During the first hour, add about half to the solution. During the second hour, add about a quarter of the solution. During the third hour, add about an eighth of the solution. During the fourth and fifth hours, add the
15 remainder of the solution. Add methylamine during the addition of 5-[(dimethylamino)methyl]-2-(chloromethyl)-furan hydrochloride. Add methylamine (0.18 kg) at the beginning of the addition and then seven more 0.18 kg portions, one portion about every 30 minutes, during about
20 the first 3.5 hours of the addition. When the reaction is complete, add aqueous 32% sodium acetate solution. Separate the layers and extract the aqueous layer twice with acetonitrile (3.4 L). Combine the organic layers and evaporate *in vacuo* to obtain a residue. Combine the residue
25 and methyl isobutyl ketone (2.8 L) and partially evaporate *in vacuo* before combining with methyl isobutyl ketone (15 L). Extract with aqueous 10% potassium carbonate solution. Separate the layers and extract the aqueous layer with methyl isobutyl ketone. Combine the organic layers extract
30 with water. Evaporate the organic layer *in vacuo* to give a residue. Recrystallize the residue from methyl isobutyl ketone to give the title compound.

EXAMPLE 5

35 5.1 Synthesis of 5-[(dimethylamino)methyl]-2-(chloromethyl)-furan hydrochloride

Combine 5-[(dimethylamino)methyl]-2-(chloromethyl)-furan hydrochloride (20 g, 0.1 mol) and acetonitrile (50

mL). Add hydrochloric acid (5.2 g, gas, 0.15 mol). Heat to 50°C to give the title compound as a solution.

5

EXAMPLE 66.1 Synthesis of N-methyl-N'-[2-[2-(N"-methyl-2-nitro-1,1-ethenediamine)ethyldisulfanyl]ethyl]-2-nitro-1,1-ethenediamine

10 Combine 2-nitromethylene-thiazolidine (50.0 g) and ethanolic methylamine solution (300 mL, 2/1 by weight ethanol/methylamine). Stir vigorously. Pass a stream of air (250 ml/minute) over the top of the reaction vessel. After 16 hours, add ethanol (200 mL) and methylamine (20
15 g). After 8 more hours, filter and rinse with cold ethanol to give the title compound: mp 177-180°C (dec).

20

25

30

35

WHAT IS CLAIMED IS:

5

1. A process for preparing ranitidine, comprising:
reacting 2-nitromethylene-thiazolidine with methylamine to
give a reaction mixture and then reacting the reaction
mixture with an appropriate 5-[(dimethylamino)methyl]-furan
10 derivative.

2. A process according to Claim 1 wherein the
appropriate 5-[(dimethylamino)methyl]-furan derivative is
5-[(dimethylamino)methyl]-2-(chloromethyl)-furan.
15

3. A process according to Claim 1 wherein the
appropriate 5-[(dimethylamino)methyl]-furan derivative is
5-[(dimethylamino)methyl]-2-(chloromethyl)-furan
hydrochloride.
20

4. A process according to Claim 1 wherein from 0.6 to
1.5 molar equivalents of an appropriate 5-
[(dimethylamino)methyl]-furan derivative is used.

25 5. A process according to Claim 1 wherein from 0.9 to
1.2 molar equivalents of an appropriate 5-
[(dimethylamino)methyl]-furan derivative is used.

30 6. A process according to Claim 1 wherein from 1.0 to
1.1 molar equivalents of an appropriate 5-
[(dimethylamino)methyl]-furan derivative is used.

35

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 95/15385

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07D307/52

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US,A,4 128 658 (PRICE BARRY J ET AL) 5 December 1978 cited in the application see column 10, line 48 - line 67 see column 24, line 41 - column 25, line 14; example 20	1-6
X	--- CHEMICAL ABSTRACTS, vol. 106, no. 5, 2 February 1987 Columbus, Ohio, US; abstract no. 32816u, A.S. DIAZ DEL CORAL 'An antiulcer (furanylmethylthioethyl)ethylenediamine derivative' page 528; column 1; see abstract & ES,A,544 063 (MEDICHEM S.A.) 16 January 1986 --- -/--	1-6

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- 'A' document defining the general state of the art which is not considered to be of particular relevance
- 'E' earlier document but published on or after the international filing date
- 'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- 'O' document referring to an oral disclosure, use, exhibition or other means
- 'P' document published prior to the international filing date but later than the priority date claimed

- 'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- 'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- 'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- '&' document member of the same patent family

Date of the actual completion of the international search

22 March 1996

Date of mailing of the international search report

29. 03. 96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+ 31-70) 340-3016

Authorized officer

Paisdor, B

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 95/15385

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>CHEMICAL ABSTRACTS, vol. 106, no. 9, 2 March 1987 Columbus, Ohio, US; abstract no. 67086h, A. S. DIAZ DEL CORAL 'Furfuryl aminoethyl sulfide derivatives' page 591; column 1; see abstract & ES,A,544 062 (MEDICHEM S.A.) 16 January 1986</p> <p style="text-align: center;">---</p>	1-6
Y	<p>PHARMAZIE, vol. 48, no. 2, 1993 BERLIN DE, page 143 J. KOSÁRY ET AL. 'A modified synthesis of 2-([1-methylamino)-2-nitroethenyl]amino)et hanediol' see the whole document</p> <p style="text-align: center;">-----</p>	1-6

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 95/15385

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A-4128658	05-12-78	GB-A- 1565967	23-04-80
		GB-A- 1565966	23-04-80
		AT-B- 375931	25-09-84
		AU-B- 515628	16-04-81
		AU-B- 2751977	08-02-79
		BE-A- 857388	02-02-78
		CA-A- 1099268	14-04-81
		CH-A- 651560	30-09-85
		CH-A- 641176	15-02-84
		CH-A- 642072	30-03-84
		DE-A- 2734070	09-02-78
		DE-C- 2759959	04-08-88
		DE-C- 2760097	17-08-89
		FR-A,B 2360587	03-03-78
		FR-A,B 2384765	20-10-78
		FR-A,B 2384753	20-10-78
		JP-A- 55153761	29-11-80
		JP-C- 1365594	26-02-87
		JP-A- 55153779	29-11-80
		JP-B- 61032315	25-07-86
		JP-C- 1209903	29-05-84
		JP-A- 53018557	20-02-78
		JP-B- 58040956	08-09-83
		LU-A- 77911	23-05-79
		NL-A- 7708601	07-02-78
		NL-A- 8202659	01-11-82
		SE-B- 437373	25-02-85
		SE-A- 7708521	05-02-78
		SE-B- 454882	06-06-88
		SE-A- 8205533	28-09-82
		SE-A- 8205607	01-10-82
		SE-A- 8205723	07-10-82
		SE-A- 8205933	19-10-82
		SE-A- 8205962	20-10-82
SE-A- 8206010	22-10-82		
SE-A- 8206061	26-10-82		
SE-A- 8206192	01-11-82		
SE-A- 8206461	12-11-82		
SE-A- 8206546	17-11-82		
SE-A- 8206547	17-11-82		

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/US 95/15385

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A-4128658		SE-B- 454883	06-06-88
		SE-A- 8206556	17-11-82
		US-A- 4169855	02-10-79
		US-A- 4279819	21-07-81
		US-A- 4255440	10-03-81
		JP-C- 1330579	14-08-86
		JP-A- 58219174	20-12-83
		JP-B- 60058236	19-12-85
